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Abstract
Background: Hepatoblastoma (HB) is the most common liver tumor of childhood and occurs predominantly within
the first 3 years of life. In accordance to its early manifestation, HB has been described to display an extremely low
mutation rate. As substitute, epigenetic modifiers seem to play an exceptional role in its tumorigenesis, which holds
promise to develop targeted therapies and establish biomarkers for patient risk stratification.
Results: We examined the role of a newly described protein complex consisting of three epigenetic regulators,
namely E3 ubiquitin-like containing PHD and RING finger domain 1 (UHRF1), ubiquitin-specific-processing protease
7 (USP7), and DNA methyltransferase 1 (DNMT1), in HB. We found the complex to be located on the promoter
regions of the pivotal HB-associated tumor suppressor genes (TSGs) HHIP, IGFBP3, and SFRP1 in HB cells, thereby
leading to strong repression through DNA methylation and histone modifications. Consequently, knockdown of
UHRF1 led to DNA demethylation and loss of the repressive H3K9me2 histone mark at the TSG loci with their
subsequent transcriptional reactivation. The observed growth impairment of HB cells upon UHRF1 knockdown
could be attributed to reduced expression of genes involved in cell cycle progression, negative regulation of cell
death, LIN28B signaling, and the adverse 16-gene signature, as revealed by global RNA sequencing. Clinically,
overexpression of UHRF1 in primary tumor tissues was significantly associated with poor survival and the prognostic
high-risk 16-gene signature.
Conclusion: These findings suggest that UHRF1 is critical for aberrant TSG silencing and sustained growth signaling
in HB and that UHRF1 overexpression levels might serve as a prognostic biomarker and potential molecular target
for HB patients.
Keywords: UHRF1, Hepatoblastoma, DNMT1, USP7, Histone methylation, DNA methylation, Epigenetic silencing,
Tumor suppressor genes, Biomarker
Background
Hepatoblastoma (HB) is the most common liver tumor
of childhood, with the majority of cases occurring in
children under the age of 3 years [1]. Over the last four
decades, advances in treatment protocols comprising
chemotherapy and surgery drastically improved outcome
of HB patients from a 30% to a roughly 80% overall
survival rate [2]. However, there is still a relevant sub-
group of high-risk patients presenting with distant me-
tastasis, vascular invasion, advanced tumor stages, or
unfavorable histology, whose outcome remains poor [3, 4].
In recent years, molecular markers have been shown to
improve HB risk stratification and the effort to find robust
markers that can predict outcome in HB patients con-
tinues [5, 6].
Molecularly, the development of this aggressive em-
bryonal tumor remains largely unknown. Exome sequen-
cing of primary HB revealed a surprisingly low mutation
rate of only 2.9 mutations per tumor on average, and
* Correspondence: roland.kappler@med.uni-muenchen.de
†Equal contributors
1Department of Pediatric Surgery, Dr. von Hauner Children’s Hospital,
Ludwig-Maximilians-University Munich, Lindwurmstr. 2a, 80337 Munich,
Germany
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Beck et al. Clinical Epigenetics  (2018) 10:27 
https://doi.org/10.1186/s13148-018-0462-7
there is evidence that epigenetic dysregulation plays a
key role in HB development and progression [7]. Aber-
rant epigenetic silencing of tumor suppressor genes
(TSGs) and overexpression of epigenetic regulators of
gene silencing such as histone deacetylases (HDACs) ap-
pear to be important drivers of this disease [8]. In par-
ticular, the silencing of the TSGs hedgehog-interacting
protein (HHIP), insulin-like growth factor-binding pro-
tein 3 (IGFBP3), and secreted frizzled-related protein 1
(SFRP1) have been shown to deregulate pivotal pathways
of embryonic development, thus promoting HB patho-
genesis [9, 10]. While there is evidence that DNA
methylation and repressive histone modifications are re-
sponsible for aberrant silencing of those genes, the mo-
lecular mechanisms through which those epigenetic
changes are conveyed and maintained remain largely
elusive.
We recently discovered a protein complex that is in-
volved in aberrant DNA methylation and repression of
TSGs in a human colon adenocarcinoma cell line [11].
The complex comprises three subunits, namely DNA
methyltransferase 1 (DNMT1), ubiquitin-specific-
processing protease 7 (USP7), and E3 ubiquitin-like con-
taining PHD and RING finger domain 1 (UHRF1)
(Fig. 1a). Those three proteins are capable of forming a
trimeric repression complex through their specific bind-
ing domains and carry out distinct functions within the
complex. DNMT1 effectively methylates DNA on CpG
islands and maintains DNA methylation patterns
throughout the cell cycle [12, 13]. USP7 has been shown
to enhance DNMT1 function and to stabilize UHRF1
levels by preventing its degradation [11]. While UHRF1
has no chromatin or DNA methylation activities itself, it
functions as a crucial guide for DNMT1 and USP7 by
binding to both via its SET- and RING-associated (SRA)
domain. Through this domain, UHRF1 is also capable of
recognizing hemi-methylated DNA, thereby recruiting
the complex to hemi-methylated CpGs and maintaining
DNA methylation throughout the genome [14].
Furthermore, UHRF1 is involved in histone modifica-
tion, as it recognizes the repressive histone H3 lysine 9
methylation mark (H3K9me2) via its tandem tudor do-
main (TTD), thus facilitating the maintenance of this
mark and the formation of heterochromatin [15, 16].
UHRF1 is also able to form a complex with HDAC1, an-
other facilitator of histone-driven gene repression [17].
Because of this dynamic crosstalk between histone and
DNA modifications, UHRF1 occupies a unique role
when it comes to long-term silencing of genes [18].
Overexpression and dysregulation of UHRF1 are com-
mon features in a variety of human malignancies, and
UHRF1-mediated silencing of TSGs appears to drive
tumorigenesis in a disease-specific context [19]. In fact,
UHRF1 is so widely overexpressed in solid tumors that
it has been suggested as a universal biomarker for cancer
[20]. However, the challenge lies in deciphering the
disease-specific context in which UHRF1 conveys its
oncogenic properties.
Here, we show the trimeric UHRF1 complex to be lo-
cated on the promoter regions of HHIP, IGFBP3, and
SFRP1 in HB cells, thereby leading to strong repression
of those pivotal HB-associated TSGs through DNA
methylation and histone modifications. Knockdown of
UHRF1 results in demethylation of promoter regions,
loss of the repressive H3K9me2 mark, and subsequent
re-expression of the abovementioned TSGs in HB cells.
Furthermore, we show that UHRF1 knockdown facili-
tates proliferation impairment and global transcriptional
Fig. 1 a Schematic overview of the trimeric complex comprising
UHRF1, USP7, and DNMT1. Involved protein interactions and protein
domains according to Felle et al. are shown [11]. b, c Chromatin
immunoprecipitation (ChIP) was performed with HUH6 cells and the
indicated antibodies. The average of two independent ChIP
experiments for b DNMT1, UHRF1, and USP7 as well as c H3K9me2,
H3K4me2, and RNAPII is shown. Standard deviations, genes of
interest, and antibodies used for ChIP are indicated. The enrichment
of specific IP versus IgG background is plotted
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changes in HB cells. Finally, we reveal overexpression of
UHRF1 in primary HB to be associated with poor pa-
tient outcome and established risk stratification criteria.
These findings suggest that UHRF1 is critical for aber-
rant TSG silencing and sustained growth signaling in
HB and that UHRF1 expression levels might serve as a
prognostic biomarker for HB patients.
Methods
Patients
A total of 40 liver tumor specimens were obtained from
pediatric patients undergoing surgical resection in our
department. Matching normal liver was available from
seven patients. Written informed consent was obtained
from each patient, and the study protocol was approved
by the Committee of Ethics of the Ludwig Maximilian
University of Munich.
Cell culture and transfection
The human hepatoblastoma cell lines HUH6 (Japanese
Collection of Research Bioresources, JCRB, Osaka,
Japan), HepT1 (provided by Dr. T. Pietsch), and HepG2
(ATCC, Manassas, USA) were cultured under standard
conditions in RPMI 1640 growth media (Invitrogen,
Carlsbad, CA, USA), supplemented with 10% fetal calf
serum, 100 U/mL penicillin, and 100 μg/mL strepto-
mycin at 37 °C in a 5% CO2 incubator. For knockdown
experiments, 2 × 106 cells were electroporated for 10 ms
at 350 V with either siRNA targeting UHRF1 (siRNA
#s26553, Applied Biosystems, Darmstadt, Germany) or
appropriate negative control siRNA (siGENOMEN non
targeting siRNA #1, Thermo Scientific, Karlsruhe,
Germany) in a final concentration of 80 pmol.
RNA isolation, reverse transcription, and qRT-PCR
Total RNA was isolated 48 h after transfection using
TriReagent (Sigma-Aldrich, Steinheim, Germany) ac-
cording to the manufacturer’s instructions. Two micro-
grams of total RNA was reverse transcribed into cDNA
using random hexamer primer (Roche Diagnostics,
Penzberg, Germany) and SuperScriptII Reverse Tran-
scriptase (Invitrogen, Karlsruhe, Germany). PCR amplifi-
cations on the Master cycler ep gradient (Eppendorf,
Hamburg, Germany) using iTaq-SYBR Green-Supermix
(Bio-Rad, Hercules, CA) were performed in doublets as
described previously [21]. The following primer pairs
(5′–> 3′ orientation) were used: UHRF1, CTCCACGTC-
CAGGCCG, TGGAGTTCATCTGGACCACG; HHIP,
TGTACATCATTCTTGGTGATGGG, AGCCGTAGCA
CTGAGCCTGT; IGFBP3, GTCCAAGCGGGAGACA-
GAATAT, CCTGGGACTCAGCACATTGA; SFRP1, CA
TGACGCCGCCCAAT, GATGGCCTCAGATTTCAAC
TCG; and TBP, GCCCGAAACGCCGAATAT, CCGTG
GTTCGTGGCTCTCT. Data were normalized to the
expression level of the housekeeping gene TATA-Box-
binding protein (TBP). For calculation of the relative
mRNA expression level, the ΔΔCT method was used
and expressed as fold change relative to the correspond-
ing control sample [22].
Western blot analysis
Forty-eight hours after transfection, cells were harvested
with ice-cold lysis buffer (0.2 M KCl, 0.03 M Tris, pH
7.25) containing proteinase inhibitor cocktail (Roche
Diagnostics). Lysates were boiled in equal volumes of
loading buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 20%
glycerol, and 10% ß-mercaptoethanol), and 20 μg of pro-
tein was separated in a 8–12% gradient Tris-glycine gra-
dient gel (Novex, San Diego, CA, USA) under reducing
conditions and transferred to nitrocellulose membranes
(GE Healthcare, Piscataway, USA). Afterwards, mem-
branes were blocked at room temperature with PBS con-
taining 0.1% Tween and 5% non-fat dry milk to block
non-specific binding for 2 h. Membranes were incubated
with primary antibodies (rabbit anti-human ß-actin, Cell
Signaling Technology, Danvers, USA; mouse anti-human
UHRF1, generously provided by Dr. C. Bronner, Institute
of Genetics and Molecular and Cellular Biology, Stras-
bourg, France) at 4 °C overnight, followed by a 1-h incu-
bation with the corresponding secondary antibodies
(goat anti-rabbit-HRP and goat anti-mouse-HRP, both
Dako Cytomation, Hamburg, Germany) at room
temperature. For chemiluminescent detection, the ECL
Plus Western detection kit (GE Healthcare) was used.
Protein bands were detected by autoradiography using
the high-performance autoradiography Hyperfilm™ MP
(GE Healthcare).
Methylation-specific polymerase chain reaction (MSP)
Genomic DNA was extracted by phenol/chloroform
after proteinase K treatment. Two micrograms of puri-
fied genomic DNA was used for bisulfite-mediated con-
version of unmethylated cytosine using the Epitec
Bisulfite Kit (Qiagen, Hilden, Germany). For MSP,
bisulfite-treated DNA was amplified with primers spe-
cific for the methylated (M) and unmethylated (U) pro-
moter region of either the HHIP (from − 230 to − 87 bp
upstream of the transcriptional start site), the IGFBP3
(from − 180 to − 13 bp upstream of the transcriptional
start site), or the SFRP1 (from + 36 to + 175 bp down-
stream of the transcriptional start site) gene. As a con-
trol for MSP, we used in vitro methylated genomic DNA
that has been treated for 4 h with 40 U CpG methyl-
transferase (M. SssI), NEBuffer2 (10×), and SAM (1:20)
at 37 °C, followed by heat inactivation for 20 min at
65 °C. For MSP, we used 1 U hot start Taq polymerase
(Thermo Scientific, Schwerte, Germany), 1× hot start
Taq buffer, 2 mM dNTPs, 1.5 mM MgCl2, 100 ng
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bisulfite-treated DNA, and 500 nM of the following forward
and reverse primers (5′–> 3′ orientation) and annealing
temperatures: HHIP-M-F, AGTAGTCGGGTATGTTCG
GAATTTTC and HHIP-M-R, GAACCTTCGAAACCAAC
CTCG at 53 °C; IGFBP3-M-F, GCGAGTTTCGAGTTG
TACGTTTTC and IGFBP3-M-R, GCCGACCGCTATATA
AAAACCG at 61 °C; SFRP1-M-F, TTTGTAGTTTTCGGA
GTTAGTGTCGC and SFRP1-M-R, CGACCCTCGACC
TACGATCG at 58 °C; HHIP-U-F, TTGTAGTAGTTGGG
TAGTTTTGGAATTTTT and HHIP-U-R, AAACCTTAA
AACCAACCTCAAAA at 53 °C; IGFBP3-U-F, TTGGG
TGAGTTTTGAGTTGTATGTTTTT and IGFBP3-U-R,
AAACACACCAACCACTATATAAAAACCAAA at 61 °C;
and SFRP1-U-F, TTTTGTAGTTTTTGGAGTTAGTGTT
GTGTG and SFRP1-U-R, CAATAACAACCCTCAACCTA
CAATCAA at 58 °C. MSP primer design was accomplished
using Methyl Primer Express (Applied Biosystems) using the
following criteria: CpG percentage > 55%, observed/expected
CpG > 65%, and CpG length > 300 bp. MSP reactions were
carried out at the following conditions: hot start at 94 °C for
4 min, followed by 38 cycles of 94 °C for 30 s, gene-specific
annealing temperature (see above) for 30 s, 72 °C for 45 s,
and final extension at 72 °C for 10 min. One percent agarose
gel electrophoresis was performed to visualize DNA
amplicons.
Pyrosequencing
For pyrosequencing, 100 ng bisulfite-treated DNA was
first amplified in a PCR reaction, using 1 U hot start Taq
polymerase (Thermo Scientific), 1× hot start Taq buffer,
2 mM dNTPs, 1.5 mM MgCl2, 100 ng bisulfite-treated
DNA, and 500 nM of the following forward and reverse
primers (5′–> 3′ orientation) and annealing temperatures:
HHIP-F, GGGAGGAGAGAGGAGTTT and HHIP-R,
AACCAACCTCCAAAATACTAAACC at 55 °C; IGFBP3-
F, TGGTTTTTTGAGATTTAAATGTAAGTTAGA and
IGFBP3-R, ATCACCCCAATCACTCCTA at 57 °C;
SFRP1-F, GGAGTTAGAGATTAGTTTGGTTAATATGG
and SFRP1-R, AAAAACCTAAATCATACTTACAACC at
54 °C; and LINE1-F and LINE1-R (assay X58075, Qiagen)
at 55 °C. PCR reactions were run at 95 °C for 4 min and
45 cycles of 95 °C for 20 s, gene-specific annealing
temperature (see above) for 20 s, and 72 °C for 30 s. PCR
products were sequenced with the corresponding sequen-
cing primers HHIP-Seq, TTTAGGATTGAGTTTTTGTT
TTAAG; IGFBP3-Seq, TTGGGTTATTTAGGTTTTATAT
AG; and SFRP1-Seq, GGTAAGAGGTTGTAATTTTAG
TTAT using PyroMark Gold Q24 reagents (Qiagen).
Chromatin immunoprecipitation (ChIP)
8.0 × 106 HUH6 cells were transfected with siRNA
against UHRF1 or corresponding non-target siRNA and
subsequently seeded in 15-cm plates. After 48 h, the
protein-DNA complexes were cross-linked with 1%
formaldehyde for 10 min. The cross-linked reaction
was quenched with Glycine Stop-Fix Solution for
5 min. Cell lysis, enzymatic digest (5 min), chromatin
immunoprecipitation with 2 μg of antibody against
di-methylated H3K4, di-methylated H3K9, RNA-Pol2
(all from Active Motif, La Hulpe, Belgium), and
mouse IgG (Santa Cruz, Heidelberg, Germany), re-
spectively, as well as final elution, cross-link reversal,
and proteinase K digestion, were performed accord-
ing to the manufacturer’s protocol (catalog no.
53009, Active Motif ). Chromatin samples were sub-
jected to a DNA clean-up step using the QIAquick
PCR Purification kit (QIAGEN). Real-time PCR was per-
formed on purified DNA from each of the ChIP reactions
using primer pairs for loci of the promoter region of
the HHIP gene, the IGFBP3 gene, the SFRP1 gene,
and the ACTB gene. Primer pairs used in this study
were the following: HHIP_ChIP_F, TTCCCACCTCCT
ACGGCC and HHIP_ChIP_R, TCCTCTCTCCTCCCC
GCTT; IGFBP3_ChIP_F, GCTCCCTGAGACCCAAA
TGTAA and IGFBP3_ChIP_R, GCTCGGCATTCGTG
TGTACC; SFRP1_ChIP_F, ACGCCGTGATCCATTC
CC and SFRP1_ChIP_R, CGGCTCAACACCCCTTAA
AAA; and ACTB_ChIP_F, GCCAACGCCAAAACT
CTCC and ACTB_ChIP_R, CAGTGCAGCATTTTT
TTACCCC.
Cell viability assay
To assess cell proliferation, a 3-(4,5-dimethyl-2-thiazo-
lyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)-based
protocol was used. Directly after electroporation, cells
were seeded at a density of 2500 (HUH6 and HepT1) or
5000 (HepG2) cells per well in a 96-well format (Nunc,
Wiesbaden, Germany) in 100 μL RPMI medium. Ten
microliters of MTT labeling agent (5 mg/mL, Sigma)
was added to each well and incubated at 37 °C for 4 h.
One hundred microliters of a SDS-HCl solution was
added to each well and mixed thoroughly. Microplate
was incubated overnight at 37 °C in a humidified cham-
ber. The absorbance of this colorimetric reaction was
quantified on the GENios reader (Tecan, Männedorf,
Switzerland) by measuring at a wavelength of 595 nm.
Cell migration assay
Transfected HB cells were seeded into 12-well plates
and grown to complete confluency. A wound of approxi-
mately 1 mm was inflicted to cell monolayers with a pip-
ette tip. The wells were washed with PBS to remove
detached cells and incubated at 37 °C for a maximum
time of 120 h. Images were taken every 24 h after
scratching, and the wound widths were measured with
ImageJ (Rasband, W.S., ImageJ, US National Institutes of
Health, Bethesda, MD, USA).
Beck et al. Clinical Epigenetics  (2018) 10:27 Page 4 of 11
RNA sequencing
Total RNA of siUHRF1 and control transfected HUH6
cells was quality checked and quantitatively measured
using the RNA 6000 nanokit on a 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA). Coding
transcriptomes were enriched from 1 μg total RNA in
solution with TruSeq non-stranded RNA v2 kits (Illu-
mina, San Diego, CA, USA) and sequenced as 100 bp
paired-end runs on a HiSeq2500 system (Illumina) gen-
erating 35–79 million mapped reads. The STAR aligner
v 2.4.2a [23] with modified parameter settings (–two-
passMode=Basic) is used for split-read alignment against
the human genome assembly hg19 (GRCh37) and UCSC
knownGene annotation. To quantify the number of
reads mapping to annotated genes, we use HTseq-count
v0.6.0 [24]. The R Bioconductor package DESeq2 [25]
with modified standard settings (no fold-change shrink-
age) is used to investigate differences in gene expression.
Gene set enrichment analysis
Enrichment analysis of gene ontology and hallmark gene
sets was performed by using the top 1000 differentially
expressed genes of the RNA sequencing results as input
for the latest version of the Molecular Signatures Data-
base (MSigDB) developed by the Broad Institute [26].
Gene sets were selected by statistical significance (p <
0.05) and the calculated representation factor. The rep-
resentation factor is the number of overlapping genes
divided by the expected number of overlapping genes
drawn from two independent groups. A representation
factor > 1 indicates more overlap than expected of two
independent groups, and a representation factor < 1 in-
dicates less overlap than expected.
Statistical analysis
Data were expressed as mean ± standard deviation or
±standard error of the mean and statistically subjected
to Student’s unpaired t test. Kaplan-Meier estimates of
specific survival time in the various groups were com-
pared using the log-rank Mantel-Cox test. Gene expres-
sion correlation was performed with GraphPad Prism
version 6.0 using Spearman’s rank correlation. A level of
p < 0.05 was considered to be significant.
Results
UHRF1 repression complex binds to HB-specific TSG pro-
moter regions
We used chromatin immunoprecipitations (ChIP) to
identify enrichment of the UHRF1 repression complex
(Fig. 1a) on chromatin of HB cells. We found all three
complex partners, namely UHRF1, DNMT1, and USP7,
to be enriched on the promoter regions of the HB-
specific TSGs HHIP, IGFBP3, and SFRP1 (Fig. 1b). Fur-
thermore, ChIP analysis of the repressive H3K9me2 and
activating H3K4me2 histone marks showed enrichment
of H3K9me2, while H3K4me2 was not detected (Fig. 1c).
The enrichment for RNA polymerase II (RNAPII) was
negligible, indicating very low or no active transcription
of those genes. Subsequent methylation-specific poly-
merase chain reaction (MSP) revealed hypermethylated
promoter regions of those three genes (Fig. 2a). Quanti-
tative mRNA analysis of HHIP, IGFBP3, and SFRP1 con-
firmed the virtual silencing of gene expression (Fig. 2b).
In sharp contrast, the housekeeping gene ACTB did not
show any enrichment for UHRF1 and the repressive
H3K9me2 mark, but high levels of H3K4me2 and RNA-
PII, which was accompanied by an unmethylated pro-
moter and a high transcriptional activity. These data
suggest that the trimeric UHRF1 repression complex
might play a crucial role in deep silencing of the TSGs
HHIP, IGFBP3, and SFRP1 in HB via combined epigen-
etic mechanisms, comprising repressive histone modifi-
cation and DNA methylation.
UHRF1 knockdown leads to re-expression of TSGs through
epigenetic modifications
To evaluate the effect of UHRF1 depletion in HB cells,
we performed knockdown experiments, which resulted
in a strong reduction of UHRF1 both on the mRNA and
the protein level (Fig. 3a, b). Depletion of UHRF1 led to
a significant re-expression of HHIP and IGFBP3 (Fig. 3c).
While the re-expression of SFRP1 was not significant,
Fig. 2 a Methylation status (U, unmethylated; M, methylated) of the
HHIP, IGFBP3, SFRP1, and ACTB promoter region was determined for the
indicated cell lines by MSP. Representative images of MSP experiments
are shown. b Relative expression levels of indicated genes compared
to the TBP housekeeping gene in three liver tumor cell lines are given.
The average of three independent experiments is shown
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we still observed an increase of SFRP1 expression
upon UHRF1 knockdown. To further elucidate the
role of the UHRF1 repression complex, we per-
formed MSP upon knockdown of UHRF1, USP7, and
DNMT1, respectively. UHRF1 knockdown led to a
significant demethylation of DNA on the indicated
TSG promoter regions (Fig. 3d). Quantification of
those differentially methylated loci by pyrosequencing re-
vealed a methylation decrease of 25, 20, and 15% for
HHIP, IGFBP3, and SFRP1, respectively, upon UHRF1
knockdown (Fig. 3e). This decrease in methylation corre-
lates well with the strength of TSG re-expression. In
addition, UHRF1 knockdown also led to loss of the
repressive H3K9me2 mark at those loci (Fig. 3f). USP7
knockdown had no significant effect on the epigenetic
marks regulating those genes and also did not result in
gene reactivation (data not shown). To investigate the ef-
fect of those epigenetic changes and the re-expression of
TSGs on HB cell proliferation, we performed viability as-
says over the course of 1 week following the knockdown.
UHRF1-depleted HB cells showed a significant growth re-
duction in two out of three cell lines over time (Fig. 3g).
This data suggests a combined derepressive effect of
UHRF1 knockdown on TSGs by alleviating repressive
DNA and histone modifications, leading to a subsequent
growth inhibition in HB cells.
Fig. 3 a Knockdown of UHRF1 in indicated cell lines. Relative gene expression in cells transfected with siRNA against UHRF1 compared to
negative control (siNTC) after 48 h is shown. Data represents average of three independent experiments. b Western blot analysis of HepT1,
HepG2, and HUH6 cells 48 h after UHRF1 knockdown. c Relative expression levels of indicated genes in HUH6 cells 48 h after UHRF1 knockdown
compared to negative control. The average of three independent experiments is shown. d Methylation status (U, unmethylated; M, methylated)
of the HHIP, IGFBP3, and SFRP1 promoter region 48 h after UHRF1 knockdown was determined by MSP in HUH6 cells. Representative images of
MSP experiments are shown. e Pyrosequencing results of promoter regions of indicated genes in HUH6 cells 48 h after UHRF1 knockdown of
three independent experiments are shown. f ChIP analyses in HUH6 cells 48 h after UHRF1 knockdown. The relative enrichment of H3K9me2 at
the indicated gene promoter regions is shown. g Cell viability of HepG2, HepT1, and HUH6 cells as evaluated by MTT assay at the indicated time
points after UHRF1 knockdown. Values represent means ± standard deviation of three independent experiments performed in duplicates.
Statistical significance of all experiments was calculated using t test (p < 0.05)
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RNA sequencing reveals HB-specific transcriptional
changes upon UHRF1 knockdown
In order to assess the effect of UHRF1 depletion on the
transcriptome, we performed RNA sequencing of HB
cells upon UHRF1 knockdown. As expected, we found
UHRF1 to be strongly downregulated and known
UHRF1-repressed target genes [27–29] to be upregu-
lated after UHRF1 knockdown, thus emphasizing the
significance of our RNA sequencing results (Fig. 4a).
To evaluate the general effect of UHRF1 depletion in
HB cells, we then used the top 1000 differentially
expressed genes as input for the analysis of gene ontol-
ogy and hallmark gene sets (Fig. 4b). The analysis
showed significant upregulation of genes involved in the
promotion of cell differentiation and development as
well as cell adhesion. Genes involved in the p53 pathway
were also significantly upregulated, indicating activation
of this tumor suppressive pathway upon UHRF1 knock-
down. Conversely, UHRF1 depletion led to significant
downregulation of genes involved in epithelial-
mesenchymal transition (EMT), cell cycle progression,
and negative regulation of cell death. In order to evalu-
ate the functional effect of downregulated EMT genes of
UHRF1-depleted HUH6 cells, we performed cell migra-
tion assays in the identical cell line upon UHRF1 knock-
down. UHRF1-depleted cells showed a markedly slower
cell migration compared to their control-transfected
counterparts (Fig. 4e).
In recent years, LIN28B has been shown to play a piv-
otal role in HB initiation and progression [30]. Interest-
ingly, we found LIN28B and its downstream targets to
be downregulated in UHRF1-depleted HB cells (Fig. 4c).
In agreement with this finding, we detected upregulation
of LET7 species, which are commonly suppressed by
LIN28B in HB.
In HB, a prognostic 16-gene classifier has been estab-
lished that discriminates between two subclasses of tu-
mors, the so-called C1 subclass that is associated with
early tumor stage and favorable patient outcome and the
C2 subclass that is linked to metastases, vascular
Fig. 4 RNA sequencing results upon UHRF1 knockdown in HUH6 cells. Log2 fold change of a known UHRF1 target genes, c genes related to the
LIN28B pathway, and d genes highly expressed in the adverse C2 gene signature. b Significant enrichment of up- or downregulated genes
within the indicated gene ontology and hallmark gene sets. Enrichment is indicated by the corresponding representation factor of each gene set.
e Scratch assay. Representative images of HUH6 cells transfected with siRNA against UHRF1 migrating into a cell-free space at 0, 48, and 96 h
compared to negative control (siNTC). Quantitative evaluation of scratch closure shows the mean values of two independent experiments
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invasion, advanced tumor stage, and poor prognosis [5].
Since HB cell lines initially showed the adverse C2 ex-
pression signature, we looked for changes in the eight
genes that exhibit high expression levels within the C2
signature. Notably, five of those genes were downregu-
lated upon UHRF1 depletion (Fig. 4d), indicating a shift
towards the favorable C1 signature, which is associated
with low expression levels of those genes. Real-time
qPCR analysis confirmed the downregulation of C2- and
LIN28B-associated genes upon UHRF1 knockdown
(Additional file 1: Figure S1). These findings suggest a
more global role of UHRF1 in HB that goes well beyond
the activation of only a few TSGs.
UHRF1 overexpressed in high-risk HB
When we investigated the expression levels of all three
subunits of the trimeric repression complex, we found
only UHRF1 to be overexpressed in primary tumor sam-
ples and HB cell lines when compared to normal liver
tissue (Fig. 5a). Overexpression of UHRF1 has been re-
ported in a variety of human malignancies and is often
predictive for higher tumor stages and poor patient
outcome [20]. Indeed, we found that high UHRF1 ex-
pression levels were significantly associated with poor
survival in HB patients (Fig. 5b). Of note, when compar-
ing UHRF1 expression levels with previously published
expression levels of the tumor suppressor gene HHIP
[21] in primary tumor tissues and the three cell lines, we
also found a significant inverse correlation of both genes
(Fig. 5c, inset).
Interestingly, we also found tumors exhibiting the
high-risk C2 signature to be significantly associated with
high expression levels of UHRF1 (Fig. 5c). Consequently,
patients with vascular tumor invasion, the unfavorable
embryonal histology, metastases, large PRETEXT IV,
and multifocal tumors predominantly had high expres-
sion of UHRF1. These data suggest that, consistent with
findings in other solid tumors, UHRF1 expression might
be a prognostic marker for patients suffering from HB.
Discussion
Genetically, HB is a very simple tumor with one of the
lowest mutation rates ever reported for any malignancy
[31]. Characterizing HB by its genetic events has only
Fig. 5 a The relative expression of DNMT1, UHRF1, and USP7 in 40 primary HB and three HB cell lines (depicted in gray) compared to the mean of
seven normal liver tissues are given. b Overall survival was calculated as time from diagnosis to death of the disease and is plotted for 40 HB
patients. Statistical significance was calculated using the Mantel-Cox test. c Individual UHRF1 expression levels of 40 primary HBs are shown with
the occurrence of important clinicopathological characteristics depicted as black boxes below. Inset: Expression levels of UHRF1 and HHIP in
primary tumor tissues (dark blue dots) and tumor cell lines (light blue dots) were plotted against each other, and Spearman’s rank correlation
was performed
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limited significance when it comes to risk stratification
and treatment selection. In addition, genetic mutations
do not explain HB tumorigenesis sufficiently and previ-
ous studies made clear that epigenetic phenomena play a
key role in HB development [10, 32].
While a number of epigenetic events, such as silencing
of TSGs in HB, have been described in the past, the
underlying molecular mechanisms remain largely un-
known. Here, we identified a trimeric repression com-
plex that is located at HB-specific TSG sites and is
capable of conveying strong transcriptional repression of
those genes by combined histone and DNA modifica-
tion. Knockdown of UHRF1, which appears to be the
critical subunit of the trimeric complex, leads to histone
and DNA demethylation, re-expression of TSGs, and
growth inhibition in HB cells. Reduced viability upon
knockdown might be a result of the downregulation of
genes involved in cell cycle progression and the negative
regulation of cell death. UHRF1 has been shown to be a
negative regulator of the p53 tumor suppressor pathway,
and growth inhibition in HB cells might be augmented
by the activation of this pathway following UHRF1 de-
pletion [33]. Knockdown-related upregulation of genes
involved in cell differentiation and development might
be a combined effect of p53 activation and the re-
expression of TSGs that are capable of blocking aberrant
growth signaling in HB cells. Notably, UHRF1 knock-
down led to downregulation of the HB-initiating LIN28B
pathway and induced a shift towards the more favorable
C1 signature. It also led to the upregulation of genes in-
volved in cell adhesion and downregulation of EMT-
related genes, thus promoting a more anti-metastatic
phenotype. Our results strongly indicate that UHRF1
represents an interesting molecular target for novel
treatment strategies in HB.
As epigenetic aberrations are potentially reversible, a
number of epigenetic therapy approaches have been de-
veloped in the last few years, some of which have shown
great promise in the treatment of cancer [34]. In fact, we
have recently shown that HDAC inhibition constitutes a
potential epigenetic treatment option for high-risk HB
patients [8]. Targeting UHRF1 in HB holds the potential
to further improve patient outcome, while reducing
doses and toxicities of untargeted chemotherapeutic
agents. Notably, the first in vitro studies of newly discov-
ered UHRF1 inhibitors have shown encouraging results
in several cancer cell lines [35–38].
Furthermore, UHRF1 overexpression seems to be a
common feature in many malignancies and has therefore
been suggested as a universal biomarker for cancer [20,
39–41]. Our systematic expression analysis of a large set
of primary HB uncovered UHRF1 overexpression to be a
potential high-risk feature of HB, as high UHRF1 expres-
sion levels were significantly correlated with poor survival
in HB patients. Moreover, the C2 subtype of the 16-gene
signature that has been shown to predict poor prognosis
in HB was also significantly associated with high UHRF1
expression.
Conclusions
Collectively, our findings suggest that UHRF1 is critical
for aberrant epigenetic modifications and sustained
growth signaling in HB. The unique capability of UHRF1
to convey repressive DNA and histone modifications
highlights its potential to induce deep TSG silencing and
other oncogenic events. UHRF1 therefore constitutes a
promising target for novel therapeutic approaches in HB
patients. Its overexpression in patients with high-risk
features makes UHRF1 also a strong candidate for a
prognostic biomarker in HB.
Additional file
Additional file 1: Figure S1. Relative RNA expression levels of indicated
genes in HUH6 cells 24 h after UHRF1 knockdown compared to control-
transfected cells. Data were normalized to the expression level of the
housekeeping gene TBP. The average of two independent knockdown
experiments is shown. Statistical significance of all experiments was
calculated using t test (p < 0.05). (PNG 110 kb)
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